TCRX

TScan Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$0.17

Price (1 Year)

$1.26 $0.17

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %18.6 / %30
Non-compliant assets / Total market cap %54.5 / %30
Non-compliant revenue / Total income %49.5 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.

Website

Analysis (Turkish): TCRX Hissesi Caiz mi, Helal mi? TScan Therapeutics, Inc. Katılım Analizi